Our results suggest that at least a subset of thymic carcinomas and TNETs may be responsive to somatostatin analogue treatment or SSTR2 antibody-drug conjugates while type A and B3 thymomas and micronodular thymomas with lymphoid stroma are less likely to express SSTR2 and may not respond to such treatments. The gene discussed is SSTR2; the disease is thymic carcinoma.